ReviewJournal of pharmaceutical analysis2026
Recent advances in proteomic strategies for target identification of traditional Chinese medicine.
Review in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional Chinese medicine (TCM) has played an indispensable role in health intervention and disease treatment. Identifying the target proteins of TCM is crucial to clarifying therapeutic mechanisms. One approach taken to enhance the breadth, depth, and precision of studies on the active cellular pathways induced by TCM is to use proteomics to reveal potential drug targets with direct interactions. Proteomic strategies facilitate identifying and characterizing target binding proteins relevant to metabolic pathways, which involves enriching the complex of small molecule and their targets based on the affinity, as well as utilizing the changes in physicochemical properties of target proteins that occur due to drug binding for proteomic identification and quantification. Probe labeling and enrichment technologies have accelerated the field of chemical proteomics. Technologies focused on measuring the changes in target proteins have been widely extended into several different approaches, and these now drive the establishment of further strategies. This review summarizes the advances in proteomics strategies mainly based on mass spectrometry (MS) for the identification of TCM targets to the present. Enhancing the application of proteomics would provide a new viewpoint on TCM treatment, while underscores the potential of TCM as biological probes and sources of novel drug candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.